Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Stockholders for Protagonist Therapeutics, Inc., held on May 27, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Newark, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders, both of which were approved:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2024 Annual Meeting.
- Sarah A. O'Dowd: 38,323,022 votes For; 306,101 votes Withheld.
- William D. Waddill: 34,282,286 votes For; 4,346,837 votes Withheld.
- Lewis T. "Rusty" Williams, M.D., Ph.D.: 34,296,520 votes For; 4,332,603 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 41,608,911
- Votes Against: 4,897
- Abstain: 124
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the definitive proxy statement filed on April 14, 2021, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2021 fiscal year.